Trimegestone + 17b Estradiol

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
84
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Postmenopause

Conditions

Postmenopause

Trial Timeline

Feb 1, 2005 โ†’ Mar 1, 2007

About Trimegestone + 17b Estradiol

Trimegestone + 17b Estradiol is a approved stage product being developed by Pfizer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00195455. Target conditions include Postmenopause.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00195455ApprovedCompleted